Source link : https://www.newshealth.biz/health-news/fda-approves-lymphir-for-r-r-cutaneous-t-cell-lymphoma/
The US Food and Drug Administration has approved denileukin diftitox-cxdl (Lymphir, Citius Pharmaceuticals) for adults with relapsed or refractory stage 1-3 cutaneous T-cell lymphoma after at least one prior systemic therapy. The immunotherapy is a reformulation of denileukin diftitox (Ontak), initially approved in 1999 for certain patients with persistent or recurrent cutaneous T-cell lymphoma. In […]
Author : News Health
Publish date : 2024-08-09 09:27:31
Copyright for syndicated content belongs to the linked Source.
Categories